Abemaciclib (Verzenios)

Status:
Red
Decision Date:
March 2019
 

Comments

RED:

  • NICE TA563 -  with aromatase inhibitor for previously untreated hormone receptor-positive, HER2 negative, locally advanced or metastatic breast cancer.
  • NICE TA579 - with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine therapy. (Decision date - June 2019)
  • NICE TA725 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.This guidance updates and replaces NICE TA579 (Decision date - Oct 2021)
  • NICE TA810 - Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence (Decision date - August 2022)

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app